Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.79 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273394 | 0.88 | ELANE (1.00) | ELANECCR1CYP2C9 | |
| SCHEMBL3147872 | 0.87 | ELANE (0.60) | ELANECYP2C9CYP3A4 | |
| SCHEMBL596435 | 0.85 | ELANE (0.59) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2275517 | 0.85 | ELANE (0.77) | ELANECCR1CYP2C9CYP3A4 | |
| SCHEMBL985971 | 0.79 | ELANE (0.83) | ELANECYP2C9CYP3A4 | |
| SCHEMBL17378390 | 0.79 | ELANE (0.83) | ELANECYP2C9CYP3A4 | |
| SCHEMBL987063 | 0.79 | ELANE (0.82) | ELANECCR1 | |
| SCHEMBL27872087 | 0.79 | ELANE (0.82) | ELANECCR1 | |
| SCHEMBL18879434 | 0.78 | ELANE (0.82) | ELANECYP2C9CYP3A4 | |
| SCHEMBL1604508 | 0.78 | ELANE (0.81) | ELANECCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998984-B2 | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2011-08-16 | — | — | US | claimed |
| EP-2018375-B1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2010-03-03 | — | — | EP | claimed |
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| EP-2018375-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | Astra Zeneca AB (SE) | 2009-01-28 | — | — | EP | claimed |
| WO-2007129962-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-7998984-B2 | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2011-08-16 | — | — | US | disclosed |
| EP-2018375-B1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-2018375-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | Astra Zeneca AB (SE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007129962-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, SERPINB6 | ELANE 2/4885CCR1 346/4885CYP2C9 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.